• Tarun Singhal, Shahamat Tauhid, Shelley Hurwitz, Mohit Neema, and Rohit Bakshi.
• Departments of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
• J Neuroimaging. 2017 Jan 1; 27 (1): 33-36.

BackgroundSpinal cord atrophy occurs early in the multiple sclerosis (MS) disease course, is closely related to physical disability, and is a putative neuroprotective therapeutic outcome measure.ObjectiveThis pilot study explored glatiramer acetate (GA)'s effect on spinal cord volume in patients with relapsing-remitting MS (RRMS).MethodsFifteen patients receiving daily subcutaneous GA were prospectively followed. At baseline, age was 43.6 ± 7.4 years, Expanded Disability Status Scale (EDSS) score was 1.4 ± 1.5, timed 25-foot walk (T25FW) was 4.7 ± 1.1 seconds, and time on GA was 2.1 ± 3.1 years. Healthy controls (n = 10) with similar age and sex to the patients were also enrolled. The spinal cord was imaged at baseline and one year later with 3T magnetic resonance imaging. An active surface method measured the C1-C7 spinal cord volume from which we calculated the normalized area.ResultsThe spinal cord area showed no significant change in the MS group over one year (P = .19). Furthermore, the change in the spinal cord area did not differ significantly between the MS and control groups over one year (P = .26). In the MS group, the EDSS score (P = .44) and T25FW (P = .92) did not change significantly on-study.ConclusionIn this pilot study of RRMS, GA therapy was not associated with any ongoing spinal cord atrophy or any difference in the one-year rate of spinal cord area change versus healthy controls. These results paralleled the lack of clinical worsening and may reflect a treatment effect of GA. Further studies are needed to confirm these preliminary findings.© 2016 The Authors. Journal of Neuroimaging published by Wiley Periodicals, Inc. on behalf of American Society of Neuroimaging.

23 keywords...

hide…